Sarah Sousa Ferreira

Sarah Sousa Ferreira

Auto-generated profile, based on publicly available information

Sarah Sousa Ferreira

Universidade Federal da Paraíba, Brasil

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2015 in Acta Biológica Colombiana
Verified
Journal Article
Open access
PAPedro Aquino
Pedro Aquino
FFFernando Gomes Figueredo
Fernando Gomes Figueredo
NPNara Pereira
Nara Pereira
ENEloiza Nascimento
Eloiza Nascimento
AMAna Martin
Ana Martin
Irwin Rose Alencar de MenezesIrwin Rose Alencar de Menezes
Irwin Rose Alencar de Menezes

1 May 2015 in European Journal of Integrative Medicine
Verified
Journal Article
Closed access
PAPedro Everson Alexandre de Aquino
Pedro Everson Alexandre de Aquino
NPNara Luana Ferreira Pereira
Nara Luana Ferreira Pereira
FFFernando Gomes Figueredo
Fernando Gomes Figueredo
SFSarah Sousa Ferreira
Sarah Sousa Ferreira
LLLivia Maria Garcia Leandro
Livia Maria Garcia Leandro
EMEdinardo Fagner Ferreira Matias
Edinardo Fagner Ferreira Matias

1 January 2026 in Brazilian Journal of Biology
Verified
Journal Article
Open access
POP. E. A. Oliveira
P. E. A. Oliveira
DSD. P. Silva
D. P. Silva
SFS. S. Ferreira
S. S. Ferreira
DMDaniela Priscila Marchi-Salvador
Daniela Priscila Marchi-Salvador
AFA. A. Oliveira Filho
A. A. Oliveira Filho
Introduction Since antiquity, natural products have been widely used to relieve symptoms and prevent numerous diseases. Early treatments for vascular disorders, including thrombosis, relied heavily on plant-derived substances, which later served as prototypes for the development of platelet aggregation inhibitors and coagulation-modulating agents. Among these bioactive constituents, phenolic compounds—abundantly found in various botanical sources—have gained prominence due to their well-established antioxidant properties and reported anticoagulant effects. Recent studies highlight that the structural diversity of phenolic acids, particularly cinnamic acid (CA) and its derivatives, offers a valuable chemical scaffold for developing new therapeutic agents targeting thrombogenesis and oxidative imbalance. Objective This study aimed to evaluate, in vitro, the pharmacological (anticoagulant and antioxidant) and toxicological (oxidant and cytotoxic) activities of cinnamic acid (CA) and five synthetic derivatives—4HDCN, 4MTCN, 3,4DHCN, 3,4DMCN, and 3H4MCN. Methods Anticoagulant activity was assessed using a semi-automated coagulometer by measuring clotting time after exposure of human plasma to each molecule. Antioxidant, oxidant, and cytotoxic (hemolytic) activities were determined using human erythrocytes from blood groups A, B, and O. Oxidative and antioxidant responses were quantified by spectrophotometry following exposure to phenylhydrazine as a pro-oxidant inducer. Hemolysis was evaluated at concentrations ranging from 0 to 400 mg/dL. Results In the anticoagulant assays, the derivative 3,4DHCN exhibited the strongest activity, prolonging clotting time to 176.6 s, slightly surpassing 3,4MTCN (165.6 s). All molecules demonstrated low or negligible oxidizing activity (<7.1%). Regarding antioxidant potential, 4MTCN showed the most effective protection against phenylhydrazine-induced oxidation, reducing oxidative damage to 8.7%. None of the tested compounds induced moderate or high hemolysis at concentrations up to 200 mg/dL. However, at 400 mg/dL, CA and 4HDCN produced high hemolytic rates across erythrocyte types. In type A cells, hemolysis reached 89.4% (CA) and 76.0% (4HDCN); in type B, 64.3% and 60.5%; and in type O, 90.1% and 70.7%, respectively. Conclusion Dihydroxylated and dimethoxylated cinnamic acid derivatives demonstrated notable anticoagulant activity, minimal oxidative effects, low antioxidant capacity, and an absence of cytotoxicity in human erythrocytes at therapeutically relevant concentrations. These findings indicate that such molecules represent promising candidates for the development of new anticoagulant agents with favorable safety profiles.

19 April 2022 in Revista Univap
Verified
Journal Article
Open access
PDF file
GNGabriella Souza Nicolau
Gabriella Souza Nicolau
MMMaria de Fátima Guedes Monteiro
Maria de Fátima Guedes Monteiro
DJDárcio Luiz de Sousa Júnior
Dárcio Luiz de Sousa Júnior
AMAna Emília Formiga Marques
Ana Emília Formiga Marques
PAPedro Everson Alexandre de Aquino
Pedro Everson Alexandre de Aquino
LLLívia Maria Garcia Leandro
Lívia Maria Garcia Leandro
O uso abusivo de medicamentos e a sua venda indiscriminada são um dos principais fatores para a resistência bacteriana, que é um grave problema à saúde. Os óleos essenciais são uma fonte de compostos bioativos que podem possuir propriedades antimicrobianas. Neste sentido, destaca-se o α-pineno, um monoterpeno que pode ser extraído dos óleos essenciais de plantas, que apresenta ação medicinal. Assim, o presente trabalho tem como objetivo avaliar a atividade antimicrobiana e moduladora do α-pineno, quando associado ao aparelho de Light Emitting Diodes (LED) frente a cepas bacterianas multirresistentes. Para tanto, foi utilizada a técnica de contato gasoso e a modulação com antibióticos e luz LED azul para determinação da atividade antimicrobiana. A concentração inibitória mínima (CIM) do composto foi de ≥ 1024 µg/mL, verificou-se, assim, um possível sinergismo do α-pineno associados à luz de LED e aos antibióticos das classes Quinolonas (Norfloxacina, Ciprofloxacina), Aminoglicosídeos (Gentamicina, Amicacina) e Beta Lactâmicos (Penicilina G e Oxacilina) frente às cepas multirresistentes de Staphylococcus aureus e Escherichia coli. Os resultados indicam que o α-pineno tem ação sinérgica quando associado aos antibióticos convencionais como a Amicacina e a Oxacilina, que obtiveram atividade satisfatória frente às cepas de E. coli e S. aureus, respectivamente. Portanto, o α-pineno pode exercer efeitos benéficos para o tratamento de infecções bacterianas relacionadas a cepas resistentes.